FINDEX Inc. (JP:3649)
:3649
Top Page
FINDEX Inc.
(3649)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥906.00
▲(9.95% Upside)
Action:DowngradedDate:03/24/26
The score is driven primarily by strong financial performance (high profitability, near debt-free balance sheet, and solid free-cash-flow quality). This is partially offset by weak technical momentum (price below key moving averages and negative MACD). Valuation is supportive with a moderate P/E and a ~2.66% dividend yield.
Positive Factors
Conservative balance sheet
FINDEX's near-zero debt and high equity base materially reduce financial risk and interest burden, giving the company durable flexibility to fund operations, buybacks, or M&A without leverage strain. This conservatism supports resilience through economic cycles and preserves strategic optionality.
Negative Factors
Inconsistent revenue growth
Historic variability in topline growth shows demand sensitivity in parts of FINDEX's end markets. While profitability is strong, inconsistent revenue undermines longer-term growth visibility, complicating capacity planning and the predictability of scale-driven margin gains across multiple-year planning horizons.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
FINDEX's near-zero debt and high equity base materially reduce financial risk and interest burden, giving the company durable flexibility to fund operations, buybacks, or M&A without leverage strain. This conservatism supports resilience through economic cycles and preserves strategic optionality.
Read all positive factors
FINDEX Inc. (3649) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥21.85B
Dividend Yield1.75%
Average Volume (3M)66.40K
Price to Earnings (P/E)18.1
Beta (1Y)0.66
Revenue Growth-2.05%
EPS Growth-9.92%
CountryJP
Employees311
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)16.35
Shares Outstanding26,608,800
10 Day Avg. Volume40,110
30 Day Avg. Volume66,396
Financial Highlights & Ratios
PEG Ratio1.72
Price to Book (P/B)4.19
Price to Sales (P/S)3.73
P/FCF Ratio14.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)56.7
Revenue Forecast (FY)¥7.00B
FINDEX Inc. Business Overview & Revenue Model
Company Description
FINDEX Inc. (3649) is a leading Japanese company specializing in the development and provision of medical information systems. The company focuses on creating software solutions that enhance healthcare operations, including electronic medical reco...
How the Company Makes Money
null...
FINDEX Inc. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.76B | 6.11B | 5.84B | 5.19B | 4.54B | 4.97B |
| Gross Profit | 3.67B | 3.98B | 3.55B | 3.33B | 2.72B | 2.56B |
| EBITDA | 1.84B | 2.10B | 1.82B | 1.75B | 1.28B | 1.23B |
| Net Income | 1.15B | 1.26B | 1.16B | 1.06B | 722.78M | 636.03M |
Balance Sheet | ||||||
| Total Assets | 6.88B | 6.81B | 6.69B | 5.94B | 4.98B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.38B | 1.68B | 1.73B | 2.69B | 2.41B | 2.17B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00M |
| Total Liabilities | 1.16B | 1.34B | 1.08B | 1.09B | 939.06M | 1.04B |
| Stockholders Equity | 5.71B | 5.44B | 5.60B | 4.84B | 4.04B | 3.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.62B | 1.87B | 559.87M | 621.08M | 681.02M |
| Operating Cash Flow | 0.00 | 1.65B | 1.90B | 842.84M | 693.85M | 750.35M |
| Investing Cash Flow | 0.00 | -297.86M | -2.43B | -296.94M | -230.16M | -490.37M |
| Financing Cash Flow | 0.00 | -1.41B | -412.54M | -270.49M | -142.02M | -186.34M |
FINDEX Inc. Technical Analysis
Negative
824.00
Price Trends
872.54
Negative
888.72
Negative
839.36
Negative
Market Momentum
-14.25
Positive
45.17
Neutral
13.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3649, the sentiment is Negative. The current price of 824 is below the 20-day moving average (MA) of 857.40, below the 50-day MA of 872.54, and below the 200-day MA of 839.36, indicating a bearish trend. The MACD of -14.25 indicates Positive momentum. The RSI at 45.17 is Neutral, neither overbought nor oversold. The STOCH value of 13.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3649.
FINDEX Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥25.37B | 20.27 | ― | 1.39% | 9.85% | 20.83% | |
70 Outperform | ¥1.14T | 18.91 | 12.15% | 1.01% | 33.50% | 17.26% | |
69 Neutral | ¥21.85B | 18.14 | ― | 1.75% | -2.05% | -9.92% | |
63 Neutral | ¥65.67B | 228.03 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥241.79B | 26.76 | ― | 0.43% | 20.55% | 48.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥68.74B | 77.03 | 5.76% | ― | 31.95% | -40.95% |
* Healthcare Sector Average
JP:3649
FINDEX Inc.
853.00
221.26
35.02%
JP:2413
M3
1,680.50
149.05
9.73%
JP:4480
Medley
2,100.00
-817.00
-28.01%
JP:3902
Medical Data Vision Co.Ltd.
1,684.00
1,327.00
371.71%
JP:3939
Kanamic Network Co., LTD.
535.00
176.60
49.27%
JP:4483
JMDC Inc.
3,695.00
1,044.89
39.43%
FINDEX Inc. Corporate Events
FINDEX Corrects Minor Error in FY2025 Consolidated Financial Results
Mar 10, 2026
FINDEX Inc. has issued a correction to its consolidated financial results for the fiscal year ended December 31, 2025, after discovering an error in the qualitative information section of its earlier disclosure. The revision relates specifically t...
FINDEX Sets 2026–2030 Growth Plan with Higher Payouts and Stronger Shareholder Focus
Feb 12, 2026
FINDEX Inc. has unveiled a five-year Growth Strategy and Shareholder Return Policy covering 2026 to 2030 that significantly upgrades its capital allocation framework. The company will raise its target dividend payout ratio from 30% to 50%, introdu...
FINDEX Issues FY2025 Results Presentation With Strong Liability and Copyright Disclaimers
Feb 12, 2026
FINDEX Inc. has released an FY2025 financial results presentation framed strictly as informational material and not as a call to action for investors or other stakeholders. The company emphasizes that the contents, including its business plan, are...
FINDEX lifts profits, boosts dividends on steady FY2025 growth
Feb 12, 2026
FINDEX Inc. reported fiscal 2025 net sales of ¥6,109 million, up 4.6% year on year, with operating profit rising 17.3% to ¥1,790 million and profit attributable to owners of parent increasing 8.1% to ¥1,256 million, signaling improv...
FINDEX Revamps Board With New Finance and Governance Appointments
Jan 28, 2026
FINDEX Inc. has nominated three new directors, including seasoned finance executive Takahiro Yazawa as Director in charge of Finance and Investor Relations, outside director candidate Kyoko Matsuba, and outside director Akane Yui as an Audit Supe...
FINDEX Raises Year-End Dividend Forecast, Boosting Shareholder Returns
Jan 28, 2026
FINDEX Inc. has revised its dividend forecast for the fiscal year ended December 31, 2025, announcing a year-end dividend increase of ¥5.00 per share to ¥14.00, up from the previously forecast ¥9.00. This revision lifts the projecte...
FINDEX Reports Steady Growth in Medical and Government IT Installations as of Year-End 2025
Jan 20, 2026
FINDEX Inc. reported preliminary implementation results for its suite of medical and government IT products as of December 31, 2025, showing steady expansion across hospitals, clinics and local governments. Core products such as the Claio data man...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.